Key Highlights

  • Acumen Pharmaceuticals (NASDAQ:ABOS) shows USD 0.24, up 14.09%, on 33.72 million shares (relative Volume 4.42) and a Market Value of USD 17.34 million on the penny stocks screen, as of the capture on November 4, 2026.
  • Senti Biosciences (NASDAQ:SNTI) shows USD 0.19, up 13.87%, on 896,820 shares and a market value of USD 5.86 million on the penny stocks screen, as of the capture on November 4, 2026.
  • Context Therapeutics (NASDAQ:CNTX) shows USD 0.20, up 6.82%, on 1.29 million shares (relative volume 1.07) and a market value of USD 18.56 million on the penny stocks screen, as of the capture on November 4, 2026.
  • Hain Celestial (NASDAQ:HAIN) shows USD 0.13, up 12.59%, on 2.72 million shares (relative volume 1.35) and a market value of USD 12.20 million on the penny stocks screen, as of the capture on November 4, 2026.

1. Acumen Pharmaceuticals (NASDAQ:ABOS)

Acumen Pharmaceuticals (NASDAQ:ABOS) said on October 30, 2026 that its Phase 2 trial missed its primary endpoint and that it is ending the programme. ABOS is on this list because the penny stocks screen filters for very low share prices, where small orders can move a quote and spreads can be wide. Published coverage of the Quarterly Report put cash, equivalents and marketable securities at USD 78.6 million at the end of September and the quarterly net loss at USD 25.4 million, before the trial result was announced. Published coverage reported a one day fall of about 91% on October 30, a single source figure treated as approximate, which would make the latest rise a bounce from a very low base. The screen market value of USD 17.34 million is below the USD 78.6 million cash figure, simple arithmetic across a screen and a reported number. At this size a small number of trades can move the price, spreads can be wide and quoted moves can reverse, so a gain says nothing about what comes next.

2. Senti Biosciences (NASDAQ:SNTI)

Senti Biosciences (NASDAQ:SNTI) stockholders approved a Merger on October 15, 2026 that pays no cash at closing and offers contingent value rights of up to USD 60.0 million. A price below USD 1 is not a verdict on a business, but it can bring Listing Rules into play, such as the Nasdaq minimum bid price, and make financing dilutive for SNTI holders. The rights pay USD 10.0 million on a regulatory filing acceptance for SENTI-202, USD 20.0 million on FDA approval and USD 30.0 million if cumulative net sales exceed USD 200.0 million, all within seven years. Stockholders also approved a reverse split between 1-for-20 and 1-for-50. This is a small and thinly traded name, so a few trades can move the quote, spreads can be wide and a gain can reverse.

3. Theriva Biologics (NYSEAMERICAN:TOVX)

Theriva Biologics (NYSEAMERICAN:TOVX) reported cash of USD 11.3 million at June 30, 2026 against a screen market value of USD 8.44 million. For TOVX, market value and volume matter more than price: a market value of a few million USD means a small number of trades can set the quote. The company has dosed first patients in the VIRAGE2 Phase 2a trial of VCN-01 in metastatic pancreatic cancer, planned at six evaluable patients, with initial data expected by the third quarter of 2027. It plans to discuss a Phase 2 and 3 retinoblastoma trial protocol with the FDA in the third quarter of 2026, and enrolment in a trial of SYN-004 is paused pending funding. The risk is that the cash runway ends in the first quarter of 2027, so financing is likely, and a small name can see quoted moves reverse.

4. Context Therapeutics (NASDAQ:CNTX)

Context Therapeutics (NASDAQ:CNTX) reported cash of USD 43 million at June 30, 2026, which management says funds operations through the fourth quarter of 2027. CNTX is on this list because the penny stocks screen filters for very low share prices, where small orders can move a quote and spreads can be wide. Management said cash funds operations through the fourth quarter of 2027. Its lead candidate CTIM-76 received FDA Fast Track Designation in April 2026, and a Phase 1b expansion is expected to start in the first quarter of 2027. At this size a small number of trades can move the price, spreads can be wide and quoted moves can reverse, so a gain says nothing about what comes next.

5. Hain Celestial (NASDAQ:HAIN)

Hain Celestial (NASDAQ:HAIN) faces a Nasdaq deadline of March 22, 2027 to lift its shares back to USD 1.00. A price below USD 1 is not a verdict on a business, but it can bring listing rules into play, such as the Nasdaq minimum bid price, and make financing dilutive for HAIN holders. To regain compliance the shares must close at or above USD 1.00 for at least ten consecutive Business days, and the company says it may use a Reverse Stock Split if needed. Published coverage of the Annual Report put Debt of about USD 558 million due December 22, 2026 against about USD 58 million of cash, with Going Concern doubt; these figures are single source and approximate. The risk is a going concern doubt with debt due on December 22, 2026, and a quote that can move sharply on small trades.

Where Things Stand

On the evidence reviewed, Hain Celestial (NASDAQ:HAIN) and SNTI carry the most visible structural risk, with a going concern doubt and a merger paying no cash at closing, while ABOS is ending its programme after a failed trial, TOVX has a runway into the first quarter of 2027 and CNTX funds operations through the fourth quarter of 2027. All five are small names where quotes can reverse. The penny stocks screen filters for very low share prices. At these levels a small number of trades can move a quote, spreads can be wide, and listing rules, reverse splits and financing can matter more than operations. A price move says little about what comes next.